Analysts’ Weekly Ratings Changes for Nuvation Bio (NUVB)

Several brokerages have updated their recommendations and price targets on shares of Nuvation Bio (NYSE: NUVB) in the last few weeks:

• 7/22/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 7/17/2026 – Nuvation Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/7/2026 – Nuvation Bio had its price target lowered by Royal Bank Of Canada from $20.00 to $19.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – Nuvation Bio had its price target raised by Truist Financial Corporation from $12.00 to $13.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Nuvation Bio was upgraded by Zacks Research from “strong sell” to “hold”.
• 6/10/2026 – Nuvation Bio had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/26/2026 – Nuvation Bio was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Buying and Selling

In related news, insider Stacy Markel sold 125,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total transaction of $753,750.00. Following the completion of the transaction, the insider directly owned 32,591 shares in the company, valued at $196,523.73. This represents a 79.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal bought 25,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was bought at an average cost of $4.73 per share, for a total transaction of $118,250.00. Following the completion of the transaction, the director directly owned 225,000 shares of the company’s stock, valued at $1,064,250. This trade represents a 12.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 235,668 shares of company stock worth $1,419,495. 30.11% of the stock is owned by company insiders.

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.